Last reviewed · How we verify
ARI-0001 cells
ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells.
ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | ARI-0001 cells |
|---|---|
| Also known as | CART19, PEI 19-187 |
| Sponsor | Sara V. Latorre |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ARI-0001 cells are a type of CAR-T cell therapy that involves genetically modifying a patient's T cells to recognize and attack cancer cells. This approach has shown promise in treating various types of blood cancers.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R (NA)
- Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL (PHASE2)
- Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (PHASE2)
- Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |